CONTENTS

6 OVERVIEW
6 Drug Overview
7 Product Profiles
7 Opdivo : Non-small cell lung cancer (NSCLC)
27 Opdivo : Melanoma
44 Opdivo : Gastric cancer
59 Opdivo : Colorectal cancer (CRC)
73 Opdivo : Head and neck cancer
87 Opdivo : Hepatocellular carcinoma (HCC)
97 Opdivo : Bladder cancer
107 Opdivo : Glioblastoma (GBM)
115 Opdivo : Renal cell cancer (RCC)

LIST OF FIGURES
19 Figure 60: Tagrisso for non-small cell lung cancer – SWOT analysis
20 Figure 61: Datamonitor Healthcare’s drug assessment summary for Tagrisso in non-small cell lung cancer
22 Figure 62: Datamonitor Healthcare’s drug assessment summary for Tagrisso in non-small cell lung cancer
35 Figure 63: Tarceva for non-small cell lung cancer – SWOT analysis
36 Figure 64: Datamonitor Healthcare’s drug assessment summary for Tarceva in non-small cell lung cancer
37 Figure 6: Datamonitor Healthcare’s drug assessment summary of Opdivo for melanoma
39 Figure 65: Tarceva sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
51 Figure 65: Tecentriq for non-small cell lung cancer – SWOT analysis
53 Figure 66: Datamonitor Healthcare’s drug assessment summary for Tecentriq in non-small cell lung cancer
55 Figure 68: Tecentriq sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
64 Figure 69: Vargatef for non-small cell lung cancer – SWOT analysis
65 Figure 12: Datamonitor Healthcare’s drug assessment summary of Opdivo for colorectal cancer
66 Figure 70: Datamonitor Healthcare’s drug assessment summary for Vargatef in non-small cell lung cancer
68 Figure 71: Datamonitor Healthcare’s drug assessment summary for Vargatef in non-small cell lung cancer
80 Figure 72: Xalkori for non-small cell lung cancer – SWOT analysis
81 Figure 16: Datamonitor Healthcare’s drug assessment summary of Opdivo for SCCHN
82 Figure 73: Datamonitor Healthcare’s drug assessment summary for Xalkori in non-small cell lung cancer
84 Figure 74: Datamonitor Healthcare’s drug assessment summary for Xalkori in non-small cell lung cancer
93 Figure 76: Zykadia for non-small cell lung cancer – SWOT analysis
94 Figure 20: Datamonitor Healthcare’s drug assessment summary of Opdivo for hepatocellular carcinoma
98 Figure 76: Datamonitor Healthcare’s drug assessment summary for Zykadia in non-small cell lung cancer
101 Figure 22: Opdivo for urothelial bladder cancer – SWOT analysis
102 Figure 77: Datamonitor Healthcare’s drug assessment summary for Zykadia in non-small cell lung cancer
103 Figure 78: Zykadia sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
111 Figure 79: Capmatinib for non-small cell lung cancer – SWOT analysis
112 Figure 26: Datamonitor Healthcare’s drug assessment summary for Opdivo in glioblastoma
113 Figure 80: Datamonitor Healthcare’s drug assessment summary for capmatinib in non-small cell lung cancer
117 Figure 81: Datamonitor Healthcare’s drug assessment summary for capmatinib in non-small cell lung cancer
120 Figure 82: Capmatinib sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
122 Figure 83: Cemiplimab for non-small cell lung cancer – SWOT analysis

LIST OF TABLES
8 Table 1: Opdivo drug profile
10 Table 2: Opdivo pivotal trial data in non-small cell lung cancer
13 Table 3: Opdivo CheckMate-026 Phase III data in non-small cell lung cancer
15 Table 4: Opdivo ongoing late-phase clinical trials in non-small cell lung cancer
18 Table 83: Tagrisso pivotal trial data in non-small cell lung cancer
23 Table 6: Opdivo sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
25 Table 7: Opdivo patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
28 Table 8: Opdivo drug profile
30 Table 9: Opdivo pivotal trial data in melanoma
34 Table 10: Opdivo ongoing late-phase clinical trials in melanoma
40 Table 11: Opdivo sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
42 Table 12: Opdivo patient numbers for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
45 Table 13: Opdivo drug profile
46 Table 14: Opdivo pivotal trial data in gastric cancer
48 Table 15: Opdivo Phase III trials in gastric cancer
56 Table 16: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
58 Table 17: Opdivo patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
60 Table 18: Opdivo drug profile
61 Table 19: Opdivo pivotal trial data in colorectal cancer
63 Table 20: Opdivo early-phase trials in colorectal cancer
69 Table 21: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
71 Table 22: Patients treated with Opdivo across the US and five major EU markets, by country, 2016–25
73 Table 23: Opdivo drug profile
75 Figure 71: Vargatef sales for NSCLC across the five major EU markets, by country, 2017–26
77 Table 25: Opdivo ongoing late-phase trials in head and neck cancer
85 Table 26: Opdivo sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017–26
87 Table 27: Opdivo patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
88 Table 28: Opdivo drug profile
89 Table 29: Opdivo Phase III trial in HCC
91 Table 30: Opdivo Phase I/II data in HCC
99 Table 31: Opdivo pivotal trial data in urothelial bladder cancer
100 Table 32: Opdivo ongoing late-phase trials in urothelial bladder cancer
108 Table 33: Opdivo drug profile
109 Table 34: Opdivo Phase III data in glioblastoma
110 Table 35: Opdivo Phase III trials in glioblastoma
116 Table 36: Opdivo drug profile
119 Table 37: Opdivo ongoing Phase III clinical trial in renal cell cancer